Regulatory agencies such as the U.S. Food and Drug Administration (FDA) generally require chiral drugs to provide pharmacological and toxicological data for each enantiomer, and single-enantiomer products of many chiral drugs need to reach an ee value of more than 99% to be approved for marketing.